AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

CEO David Cordani highlighted Cigna's full-year revenue growth of $247 billion, a 27% increase, alongside adjusted EPS of $27.33, which fell short of expectations. He reaffirmed the company's ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Fresh off underperforming Wall Street’s expectations in the fourth quarter, Cigna said it would work to lower costs for its ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million ...

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from ...